Sujata Tyagi Dayal

CIK: 0001536908

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (60.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EBS

Emergent BioSolutions Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

EBS
Emergent BioSolutions Inc.
May 1, 2026
Sale(S)
Direct
12.8K shares at avg. $8.36$107K
EBS
Emergent BioSolutions Inc.
May 1, 2026
Sale(S)
Direct
980 shares at avg. $8.94$9K
EBS
Emergent BioSolutions Inc.
Apr 30, 2026
Award(A)
Direct
25.3K shares-
EBS
Emergent BioSolutions Inc.
Nov 7, 2025
Sale(S)
Direct
8.6K shares at avg. $10.00$86K
EBS
Emergent BioSolutions Inc.
Apr 30, 2025
Award(A)
Direct
34.4K shares-

		Type	Shares	Price		Ownership
May 1, 2026	EBS Emergent BioSolutions Inc.	Sale(S)	12,781	$8.36	$106,849	Direct
May 1, 2026	EBS Emergent BioSolutions Inc.	Sale(S)	980	$8.94	$8,761	Direct
Apr 30, 2026	EBS Emergent BioSolutions Inc.	Award(A)	25,344	-	$0	Direct
Nov 7, 2025	EBS Emergent BioSolutions Inc.	Sale(S)	8,552	$10.00	$85,520	Direct
Apr 30, 2025	EBS Emergent BioSolutions Inc.	Award(A)	34,403	-	-	Direct

1-5 of 5 transactions

About Dayal Sujata Tyagi

Dayal Sujata Tyagi (SEC CIK 0001536908) files insider reports with the SEC as Director of Emergent BioSolutions Inc. (EBS).

Signal8 holds 3 ownership filings by Dayal Sujata Tyagi, all Form 4s, filed between May 2, 2025 and May 4, 2026. Those filings report 5 transactions, from Apr 30, 2025 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dayal Sujata Tyagi's filings is in GAITHERSBURG, MD.

Recent filings by Dayal Sujata Tyagi

May 1, 2026: Open-market sales of EBS shares (2 lines, Form 4, code S).
Apr 30, 2026: Grant or award of EBS shares (Form 4, code A).
Nov 7, 2025: Open-market sale of EBS shares (Form 4, code S).
Apr 30, 2025: Grant or award of EBS shares (Form 4, code A).

Other insiders filing for Emergent BioSolutions Inc. (EBS)

DeGolyer Donald W, Director
Williams Paul Anthony, SVP, Products Business
Duatschek Stephanie, EVP, CGO
LINDAHL RICHARD S, EVP, Chief Financial Officer
Glessner Coleen, EVP, Quality & Ethics, and CPL
Hartzel William, SVP, Bioservices

How to read Form 4 transaction codes